These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21771032)

  • 1. Thyroid transcription factor-1 expression in rare cases of mammary ductal carcinoma.
    Sakurai A; Sakai Y; Yatabe Y
    Histopathology; 2011 Jul; 59(1):145-8. PubMed ID: 21771032
    [No Abstract]   [Full Text] [Related]  

  • 2. Thyroid transcription factor-1 expression in breast carcinomas.
    Robens J; Goldstein L; Gown AM; Schnitt SJ
    Am J Surg Pathol; 2010 Dec; 34(12):1881-5. PubMed ID: 21107096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.
    Sirvent JJ; Salvadó MT; Santafé M; Martínez S; Brunet J; Alvaro T; Palacios J
    Histol Histopathol; 1995 Jul; 10(3):531-9. PubMed ID: 7579801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
    Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
    Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and significanc of ERbeta and HER2 in breast cancer].
    Yang SE; Li X
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):767-8. PubMed ID: 18396690
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis.
    Miki Y; Clyne CD; Suzuki T; Moriya T; Shibuya R; Nakamura Y; Ishida T; Yabuki N; Kitada K; Hayashi S; Sasano H
    Cancer Lett; 2006 Nov; 244(1):24-33. PubMed ID: 16427184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 (HER2/neu) supraexpression in the mammary tumors.
    Moise M; Motoc A; Răducan A; Răducan S; Niculescu V; Niculescu M
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1101-5. PubMed ID: 22119832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
    Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
    Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
    Demir H; Turna H; Can G; Ilvan S
    J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
    Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.
    Yoder BJ; Wilkinson EJ; Massoll NA
    Breast J; 2007; 13(2):172-9. PubMed ID: 17319859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count.
    Weinstein MH
    Hum Pathol; 2000 Apr; 31(4):520-1. PubMed ID: 10821503
    [No Abstract]   [Full Text] [Related]  

  • 20. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
    Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
    Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.